Marex Group’s Seres Therapeutics MCRB Stock Holding History

Marex Group’s Portfolio MCRB Stock Details MCRB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-5,000	Closed	-$94.6K	–	770
2024 Q3	$94.6K	Buy	+5,000	New	+$101K	﹤0.01%	540

Other funds holding MCRB

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Vontobel Holding Zurich, Switzerland $29.1B AUM 22.79% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Marex Group's MCRB Position: Q4 2024 in Review

Marex Group sold out of Seres Therapeutics (MCRB) in Q4 2024, closing a stake of 5,000 shares — an estimated $94.6K sold.

Marex Group first reported a position in MCRB in Q3 2024 and held it in 1 quarter. The position peaked at $94.6K in Q3 2024. 69 funds tracked by Wall St. Rank hold MCRB as of Q4 2024.

Marex Group reported no remaining Seres Therapeutics position as of Q4 2024 after selling out during the quarter.
Marex Group sold 5,000 Seres Therapeutics shares in Q4 2024, an estimated $94.6K.
Marex Group first reported a position in Seres Therapeutics in Q3 2024 and held it in 1 quarter.
Marex Group's Seres Therapeutics position peaked at $94.6K in Q3 2024.
69 funds tracked by Wall St. Rank held Seres Therapeutics as of Q4 2024.

Based on Marex Group's 13F filing for Q4 2024, filed 2 Apr 2026.